Drug Delays Progression of Ovarian Cancer - TRINOVA-1/trebananib

Medpage

Published: June 13, 2013

Median progression-free survival in patients with recurrent ovarian cancer was boosted by 1.8 months with a novel targeted therapy in a phase III trial, its sponsor said.
When patients taking paclitaxel also received trebananib, a so-called peptibody drug with multiple targets in the angiopoietin axis, they experienced median progression-free survival of 7.2 months, compared with 5.4 months in patients treated with paclitaxel plus placebo, according to a statement released by Amgen.
The resulting hazard ratio of 0.66 was statistically significant in the large trial (95% CI 0.57-0.77, P<0.001), the company said.
Follow-up has not yet been sufficient to establish a difference in overall survival. Amgen said those data are expected to be available next year.
The TRINOVA-1 trial is the first of three pivotal studies with trebananib, a synthetic antibody-based agent that binds the angiopoietin-1 and angiopoietin-2 proteins and also inhibits their interaction with the Tie2 receptor. More than 900 patients are enrolled in TRINOVA-1.............